Skip to main content

Medicare GLP-1 Bridge: $50 Wegovy & Zepbound Copay Explained

Live as of July 1, 2026. The Medicare GLP-1 Bridge is a CMS demonstration running through December 31, 2027. Program details on this page are drawn from CMS and Medicare.gov and are current as of July 2026. Coverage rules can change — verify your own eligibility at Medicare.gov/glp1bridge.

For the first time, Medicare beneficiaries can get brand-name GLP-1 weight-loss drugs for a flat $50 a month. The Medicare GLP-1 Bridge, launched July 1, 2026, covers Wegovy, Zepbound, and the new oral drug Foundayo through the end of 2027. It is deliberately temporary, and the fine print on what the copay does — and does not — count toward matters. Here is how it works, who qualifies, and how it compares to the cash-pay and compounded routes most people were using before.

What Is the Medicare GLP-1 Bridge?

The Bridge is a short-term demonstration run by the Centers for Medicare & Medicaid Services (CMS). It gives eligible Medicare Part D beneficiaries access to certain GLP-1 drugs for weight loss between July 1, 2026 and December 31, 2027. CMS is running it under its demonstration authority, separate from the standard Part D benefit.

The mechanics are unusual. The Bridge operates outside the normal Part D coverage and payment flow, so your Part D plan does not carry the cost and does not have to opt in for you to get the drugs. In 2026, CMS uses a single central processor to handle prior authorization, claims, and payment to pharmacies. Practically, that means your regular plan's formulary and tiers do not govern these specific GLP-1 fills — the Bridge rules do.

Why now? Medicare has long been barred from covering drugs used purely for weight loss, which left seniors paying cash or turning to compounded alternatives. The Bridge is a workaround that also lets CMS gather utilization data ahead of a potential permanent policy. If you are new to these drugs, start with our complete GLP-1 guide and GLP-1 for weight loss overview.

Which Drugs Are Covered

As of July 2026, Medicare lists three covered products under the Bridge:

Notably absent: Ozempic and Mounjaro. Those share the same molecules as Wegovy and Zepbound but are FDA-approved for type 2 diabetes, not weight loss, so they fall outside a weight-loss demonstration. If diabetes is your primary indication, your normal Part D coverage — not the Bridge — is the relevant path; see Ozempic cost and Mounjaro cost.

Deciding between the covered options usually comes down to injection versus pill and expected weight loss. Our which GLP-1 is best for weight loss guide and semaglutide vs tirzepatide comparison walk through the tradeoffs.

The $50 Copay and Its Fine Print

Eligible beneficiaries pay a flat $50 copay per month. The number does not change as your dose escalates, which is the program's headline advantage: with standard pharmacy pricing or cash-pay plans, cost often climbs as you titrate toward a maintenance dose. Under the Bridge, a starting dose and a top maintenance dose both cost $50.

The catch is in the accounting. Because the Bridge sits outside the Part D benefit, three things are true and easy to miss:

  • The Part D deductible does not apply to Bridge drugs.
  • None of the $50 counts toward your true out-of-pocket (TrOOP) total, so it will not push you toward the annual Part D out-of-pocket cap or catastrophic coverage.
  • There is no low-income subsidy (LIS/Extra Help) for Bridge drugs, even if you qualify for Extra Help on your other medications.

If you take several costly Part D drugs, this separation is a real downside: $600 a year on GLP-1s that does not count toward your cap is $600 that does not accelerate your other coverage. For context on how weight-loss drug coverage normally works, see GLP-1 insurance coverage.

Who Qualifies

Two conditions have to be met. First, you must be enrolled in a Medicare drug plan — a standalone Part D plan or a Medicare Advantage plan that includes drug coverage. Second, you have to meet a weight-related medical threshold. Per Medicare, that is generally a body mass index (BMI) of 35 or higher, or a BMI of 27 or higher paired with a weight-related condition such as cardiovascular disease, prediabetes, or hypertension.

A prescriber has to submit a prior authorization confirming the clinical criteria before the pharmacy can dispense at the $50 copay. A KFF analysis estimated roughly 3.8 million beneficiaries could be eligible based on prior Part D enrollment data, though actual uptake will be far smaller.

Standard GLP-1 contraindications still apply, including a personal or family history of medullary thyroid carcinoma or MEN2 and a history of pancreatitis. Review GLP-1 side effects before starting, and always confirm your own status at Medicare.gov/glp1bridge or by calling 1-800-MEDICARE.

How to Get Started

There is no separate sign-up for the Bridge. The workflow is:

  • 1. Confirm your plan. You need a Medicare drug plan (Part D or MA-PD). You do not need your plan to opt in.
  • 2. See a prescriber. Discuss whether Wegovy, Zepbound, or Foundayo is appropriate and whether you meet the BMI and condition criteria.
  • 3. Prior authorization. Your prescriber submits a prior authorization to the Bridge's central processor.
  • 4. Fill at a participating pharmacy for the $50 copay.

If you are exploring providers who can prescribe, our guides to telehealth weight loss programs and GLP-1 telehealth pricing can help, but note that most cash-pay telehealth platforms do not bill Medicare — the Bridge runs through your Medicare drug coverage, not a subscription service.

How the Bridge Differs From Normal Part D Coverage

Under ordinary Part D, weight-loss drugs are excluded from coverage by statute, and even covered drugs run through your plan's deductible, tiers, and out-of-pocket cap. The Bridge inverts most of that: it covers weight-loss GLP-1s specifically, ignores your plan's formulary for these fills, charges a flat copay, and keeps the spending off your out-of-pocket ledger.

That design is what makes it a "bridge" rather than a benefit expansion. CMS built it to run on a central processor and expire on a fixed date, while it studies how many beneficiaries use GLP-1s and at what cost. The tradeoff for the low, predictable copay is that none of it helps you clear your regular Part D thresholds.

Timeline: July 2026 Through December 2027

The Bridge opened July 1, 2026 and is authorized through December 31, 2027 — roughly 18 months. CMS has said it will use the window to collect GLP-1 utilization data to share with Part D plan sponsors ahead of possible implementation of its broader BALANCE Model in Part D. In plain terms: the government is testing demand and cost before deciding whether to make GLP-1 weight-loss coverage permanent.

For beneficiaries, the practical takeaway is to not assume the $50 copay survives past 2027. If it lapses, you would fall back to cash pricing or whatever Part D policy replaces it. Build that uncertainty into any long-term treatment plan, and see cheapest semaglutide options as a fallback reference.

Bridge vs. Compounded and Cash-Pay GLP-1s

Before the Bridge, a Medicare beneficiary who wanted a GLP-1 for weight loss had two bad options: pay full retail cash price (often $500–$1,000+ a month for brand-name Wegovy or Zepbound) or use a compounded semaglutide/tirzepatide telehealth service. The Bridge beats both for eligible patients.

On price, $50/month for an FDA-approved brand drug undercuts essentially every cash-pay route. On safety, brand-name products are FDA-reviewed for identity, strength, and quality, while compounded versions are not — a distinction the FDA has spent 2026 tightening. See our guide to whether compounded semaglutide is legal in 2026 for that regulatory backdrop.

Compounded GLP-1s were never a clean fit for Medicare patients anyway: most compounding telehealth platforms explicitly exclude Medicare and Medicaid beneficiaries. For that population, the Bridge is the first realistic, low-cost, on-label path to a GLP-1 for weight loss.

Limitations and Open Questions

The Bridge is genuinely useful but narrow. It is time-limited to 18 months, covers only three products (and only the Zepbound KwikPen, not vials), excludes Ozempic and Mounjaro, provides no Extra Help subsidy, and keeps spending off your out-of-pocket cap. Supply is another open question: if demand runs hot, the covered products — especially newer ones — could face the same intermittent shortages that have dogged GLP-1s since 2023.

None of this is medical advice, and eligibility rules can shift during the demonstration. Confirm the current covered-drug list, BMI criteria, and prior-authorization steps directly at Medicare.gov/glp1bridge or 1-800-MEDICARE before making a decision.

Frequently Asked Questions About Medicare GLP-1 Bridge

The Medicare GLP-1 Bridge is a short-term CMS demonstration that gives eligible Medicare Part D beneficiaries access to certain GLP-1 weight-loss drugs for a flat $50 monthly copay. It runs from July 1, 2026 through December 31, 2027 and operates outside the normal Part D benefit, using a single central processor to handle prior authorization, claims, and pharmacy payment.

As of July 2026, Medicare lists three covered products: Foundayo (oral orforglipron tablet), Wegovy (semaglutide injection or tablet), and Zepbound (tirzepatide) in the KwikPen autoinjector only. The program does not cover single-dose Zepbound vials or single-dose pens, and it does not cover Ozempic or Mounjaro, which are approved for diabetes rather than weight loss. Confirm the current list at Medicare.gov before you fill.

A flat $50 copay per month. Unlike standard Part D cost-sharing, the copay does not rise as your dose escalates, so the price is the same at a starting dose and a maintenance dose. That flat structure is the main financial advantage over both retail pharmacy pricing and most cash-pay telehealth plans.

No. Because the Bridge sits outside the Part D benefit, the Part D deductible does not apply, and none of the $50 copay counts toward your true out-of-pocket (TrOOP) total or the annual Part D out-of-pocket limit. If you also take expensive Part D drugs, that matters: Bridge spending will not help you reach catastrophic coverage faster.

You must be enrolled in a Medicare drug plan (Part D or a Medicare Advantage plan with drug coverage) and meet a weight-related medical threshold. Per Medicare, eligibility is generally a BMI of 35 or higher, or a BMI of 27 or higher with a related condition such as cardiovascular disease, prediabetes, or hypertension. A prescriber must submit a prior authorization. Check your specific eligibility at Medicare.gov/glp1bridge or by calling 1-800-MEDICARE.

No. CMS has stated that no low-income subsidy is provided for drugs furnished under the Bridge. If you receive Extra Help, the subsidy will not reduce the $50 copay on these GLP-1 drugs, though it still applies to your other Part D medications.

There is no separate enrollment. If you are in a qualifying Medicare drug plan, talk to a prescriber about whether a covered GLP-1 is appropriate; if so, they submit a prior authorization to the central processor, and you fill at a participating pharmacy for the $50 copay. Your Part D plan does not have to opt in for you to access the drugs. Start at Medicare.gov/glp1bridge.

The Bridge is explicitly temporary. CMS is using it to collect GLP-1 utilization data ahead of a possible broader Part D policy tied to its BALANCE Model. There is no guarantee that $50 GLP-1 coverage continues after 2027, so treat the program as a bridge, not a permanent benefit, and plan for the possibility that costs change when it expires.

For most eligible Medicare beneficiaries, yes on both cost and safety: $50/month for an FDA-approved, brand-name drug beats typical cash-pay compounded pricing, and brand-name products are FDA-reviewed for quality while compounded versions are not. Compounded GLP-1s were never a clean fit for Medicare patients anyway, since most telehealth compounding platforms do not serve Medicare or Medicaid beneficiaries.

This page is informational and is not medical advice or a statement of Medicare coverage. Program details are drawn from CMS and Medicare.gov and are current as of July 2026; the Medicare GLP-1 Bridge is a temporary demonstration scheduled to run July 1, 2026 through December 31, 2027, and its terms can change. Verify your eligibility and covered drugs at Medicare.gov/glp1bridge.